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 The purpose of this study was to develop an in vivo 
pharmacokinetic model and parameters for predicting the 
concentrations of ophthalmic drugs in the anterior chamber 
after instillation into human eyes. We have already reported 
the usefulness of mathematical model including a diffusion 
process in rabbits". Timolol was used as a model ophthalmic 
drug. The concentrations of timolol and fluorescein in the 
tear fluid were determined after instillation into the eyes of 
human volunteers. The in vivo pharmacokinetic parameters 
in the tear fluid were estimated by the elimination profile 
according to a one-compartment model. The concentrations 
of timolol in the aqueous humor were obtained from the data 
previously reported"". Other parameters of timolol were 
estimated from the concentration profiles of timolol in the 
aqueous humor according to a pharmacokinetic model 
including a corneal diffusion process. The parameters for 
human were almost equal to those for rabbits reported 
previously". This mathematical model and in vivo parame-
ters will be effective to estimate the adequate regimen for 
ophthalmic chemotherapy and develop the ocular drug 
delivery systems.
plicated because it includes both slow process such as 
corneal penetration and rapid processes such as disposition 
and distribution in the tear fluid and aqueous humor","' 
In the previous report, we have successfully established 
an in vivo pharmacokinetic model including a corneal 
diffusion process in rabbits and predicted the concentra-
tions of beta-blockers in the anterior segments'). There-
fore, in the present study, we developed an in vivo 
pharmacokinetic parameters for human using the mathe-
matical model including a corneal diffusion process. 
Timolol was used as a model ophthalmic drug. Although 
timolol is widely used in the treatment of open-angle 
glaucoma as instillation droplets"), its usefulness for 
glaucoma therapy has 'been limited by topical and systemic 
side effects such as cardiovascular and respiratory compli-
cations",". It is especially necessary to control pharma-
cokinetic behavior of the instilled timolol for effective 
treatment.
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Introduction 
 In ophthalmic chemotherapy, topical application of 
drugs is the general method of choice under most circum-
stances because it gains a high drug concentration in the 
target site of anterior chamber with convenience and safet 
y4,5) 
 However, rapid eliminations of instilled drugs in the 
tear and poor permeability of cornea result in a poor 
bioavailability in an anterior segment and increased 
severity in systemic adverse effects"). Numerous attempts 
have been reported to improve the ocular delivery'-'). 
 In order to rationally design the adequate dosage regi-
men and formulation for patient, it is important to 
develop pharmacokinetic models that can evaluate the 
ocular absorption of instilled drugs","). However, the 
behaviors of instilled drug in anterior chamber is com-
Materials and Methods 
Materials. 
 Timolol (0.5% Timoptol®, 11.6 mM timolol, Banyu 
Pharmaceutical Co. Ltd., Tokyo, Japan) and fluorescein 
(Fluorecite 1®, 12 mM fluorescein, Japan Alcon Co. Ltd., 
Tokyo, Japan) were purchased commercially. Methyl-p-
hydroxybenzoate was purchased from Sigma Chemical Co. 
(St. Louis, MO, USA). All other chemicals of reagent 
grade were obtained from Nacalai Tesque Inc. (Kyoto, 
Japan). Phosphate-buffered saline (pH 7.4) was prepared 
by mixing isotonic phosphate buffer with an equal volume 
of 0.9% NaCl. 
Drug Disposition in Tear Fluid. 
 Drug solution was instilled into six and three healthy 
volunteers (23-40 years) for fluorescein and timolol, 
respectively. All experiments in the present study con-
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formed to the "Declaration of Helsinki and The Guiding 
Principles in the care and Use of Animals (DHEW 
Publication, NIH 80-23). Twenty-five microliters of drug 
solutions (timolol : 11.6 mM, fluorescein : 12 mM) were 
carefully instilled with a micropipette (Gilson Medical 
Electronics, Villiers-Bel, France) in the middle of lower 
conjunctival sac of the eye. At appropriate time after 
instillation, tear fluid samples (0.5p1) were collected by a 
glass capillary (EM minicaps®, Hirschman Laborgerate, 
Germany) from the middle of the lower marginal tear 
strip and were diluted by 50 u 1 of pH 7.4 phosphate-
buffered saline. Drug concentrations in the samples were 
determined with a high performance liquid chromatogra-
phy (HPLC) or fluorophotometer. 
Drug Determination 
 The samples of the tear fluids for timolol (50,u 1) were 
mixed with 0.1 M HCl (50 p 1) and methanol (100 p 1) 
including an internal standard (500 u g/ml methyl-p-
hydroxybenzoate). The mixtures were centrifuged at 12000 
x g for 15 min and the supernatants (50,u 1) were injected 
into a HPLC system. 
 The HPLC system (LC-6A, Shimadzu Co., Ltd., Kyoto, 
Japan) was used in a reverse-phase mode for assay. The 
stationary phase used was Cosmosil 5C18-P packed column 
(150 mm length x 4.6 mm i.d., Nacalai Tesque Inc., Kyoto, 
Japan). Mixtures of methanol and 50 mM NaH2PO4 (40: 
60 v/v) were used as the mobile phase with a flow rate of 
1.0 ml/min. Retention of drug was monitored with a UV 
spectrophotometric detector (SPD-10A, Shimadzu Co., 
Ltd.; 295 nm for timolol). Fluorescein was determined 
with a spectrofluorophotometer (RF-1500, Shimadzu Co., 
Ltd.; excitation wave length 490 nm, emission wave length 
511 nm). 
Data Analysis 
 The concentration profiles for timolol and fluorescein in 
the tear fluid were analyzed by a one-compartment model. 
The concentrations in the tear fluid (CTF) at time t are 
expressed as follows : 
 CTF = Xo exp (- KeTFt) /VTF (1) 
where Xo is the initially instilled dose, VTF is the apparent 
distribution volume in the tear fluid, KeTF is the elimina-
tion rate constant in the tear fluid. 
 The concentration profiles for timolol in the aqueous 
humor were obtained from the data reported by Phillips et 
a12). and Ellis et al.'). The data were analyzed by a pharma-
cokinetic model including a diffusion process for the finite 
dose system which considers the cornea to be a one-plane 
layer (Fig. 1). Based on this model, the Laplace trans-
forms for the amount of drug appearing in the aqueous
Fig. 1. In vivo pharmacokinetic model including a diffusion 
process for human. Abbreviation : CTF, the drug concentra-
tion in the tear fluid ; CCR, the drug concentration in the 
cornea ; CAH., the drug concentration in the aqueous humor ; 
CAHP, the drug concentration in the reservoir ;VTF, the appar-
ent distribution volume in the tear fluid ;VCR, the effective 
diffusion volume in the cornea ; VAHc, the apparent distribu-
tion volume in the aqueous humor ; VAHP, the apparent 
distribution volume in the reservoir ; DCR, the diffusion 
coefficient of drug in the cornea ; KCR, the partition coefficient 
of drug between the cornea and donor solution ; A, the 
effective diffusion area ; L, the effective diffusion length in the 
cornea ; KeTF, the elimination rate constant in the tear fluid ; 
KeAH, the elimination rate constant in the aqueous humor ; 
Kt, the transfer rate constant from the aqueous humor to the 
reservoir; Kt, the transfer rate constant from the reservoir to 
the aqueous humor.
humor (AH.o.t) are expressed as follows : 
  AHamo,,,,t = sZXOVAHC (s+Ktp~) /W (2) 
     W = VTFVAHC (s+KeTF) ((s+KeAH+Ktcp) 
          (s+Ktpc) -Kt,pKt,) sinhd 
          +sZVAHc ((s+KeAH+Ktcp) (s+Ktpc) 
           -Kt cpKt,) coshd 
          +sZVTF (s+KeTF) (s+Ktp,,) coshd 
          +s2Z2 (s+Ktpc) sinhd 
      d = L (s/DCR)°.5 
      Z = KCRVCR/d 
where DCR is the diffusion coefficient of drug in the cornea, 
KCR is the partition coefficient of drug between the cornea 
and donor solution, L is the effective diffusion length in 
the cornea, VCR is the corneal volume, s is the Laplace 
variable with respect to time, VAHC is the apparent distri-
bution volume in the aqueous humor, KeAH is the elimina-
tion rate constant in the aqueous humor, Ktcp and Ktpc are 
the transfer rate constants between the aqueous humor and 
reservoir. 
 Based on this model, the Laplace transforms for the 
amount of drug appearing in the tear fluid (TF.o,,,,t) and in
Table 1. Pharmacokinetic parameters for fluorescein and 
timolol in the tear fluid after instillation into human eyes
  Parameter Fluorescein Timolol 
 KeTF (min-') 0.16±0.01 0.18±0.01                  (0
.15) (0.18) 
  VTF (ml) 0.09±0.02 0.28±0.10                  (0.08) (0.19) 
Pharmacokinetic parameters of timolol in the tear fluid were 
not significantly different from those of fluorescein (Welch's 
t-test). 
The parameters in parenthesis were calculated from an 
average concentration time-profile of human. The parame-
ters in parenthesis for timolol were used for the estimation of 
in vivo corneal penetration parameters and pharmacokinetic 
parameters for timolol in the aqueous humor.
Fig. 2. Concentration of fluorescein and timolol in the tear 
fluid after instillation into human eyes. (•) fluorescein, (0) 
timolol. Each point represents the mean ± S.E. of at least 
three experiments.
the cornea (CR.ount) are expressed as follows : 
  TFa,a,nt = XOVTF (VAHC((s+KeAH+KtCp) (s+Ktpc) 
          -Kt ,pKtpc) sinhd 
        +sZ (s+Ktpc) coshd/W (3) 
  CRemonnt = XO Z (VAHC((s+KeAH+Ktvp) (s+Ktpc) 
          -Kt ,,pKtp,,) (coshd-1) 
        +sZ (s+Ktp,) sinhd)/W (4) 
 Apparent distribution volume and elimination rate 
constant in the tear fluid were estimated by the 
concentration-time profile in the tear fluid after instilla-
tion (equation 1) . The parameters were also calculated 
from an average concentration time-profile of three 
volunteers and were used for the estimation of in vivo 
corneal penetration parameters and pharmacokinetic 
parameters for timolol in the aqueous humor. The corneal 
elimination of drug in the tear fluid was negligible because 
the corneal permeability coefficient of timolol was much 
lower than the elimination rate constant in the tear fluid. 
 Since it is difficult to determine correctly the real 
diffusion length for penetrant, the diffusion parameter 
(D' = DcR/L/L) and the partition parameter (K' = KCR 
VCR) were defined. The penetration parameters (D', K'), 
apparent distribution volume (VAHe) , elimination rate 
constant (KeAH) and transfer rate constants in the aqueous 
humor and reservoir (Kt, Kt,,,,) were estimated using the 
equation 2 from the concentration-time profiles in the 
aqueous humor. The estimations were carried out by using 
MULTI"), a nonlinear least-squares computer program, 
and MULTI (FILT.)'), a nonlinear least-squares computer 
program based on a fast inverse Laplace transform
Table 2. In vivo corneal penetration parameters and phar-
macokinetic parameters for timolol in the aqueous humor 
after instillation into human eyes
  Parameter Human Rabbit* 
 D' (hr-') 0.32 0.33 
 K' (cm') 0.006 0.014 
 KeAH (min-') 0.013 0.057 
 Kt, (min-') 0.020 0.028 
 Kt, (min-') 0.086 0.031 
 VAN, (min-') 0.142 0.446 
* In vivo corneal penetration parameters and pharmacokine-
tic parameters in rabbit were previously reported.
algorithm. The simulation and fitting lines were calcu-
lated from equations 2, 3 and 4, and estimated parameters 
by using MULTI (FILTS)', a computer program based on 
a fast inverse Laplace transform algorithm. These pro-
grams were written by MS-FORTRAN and run on a 
personal computer (PC-9821 V10, NEC, Tokyo, Japan).
Results 
In Vivo Pharmacokinetic Model 
 Fig. 1 shows an in vivo pharmacokinetic model including 
a corneal diffusion process for predicting the concentra-
tions of ophthalmic drugs in anterior tissues such as tear, 
cornea, and aqueous humor after an instillation. In this 
model, instilled drug diffuses the cornea from the tear 
fluid to the aqueous humor with the reservoir during a 
mono-exponential elimination in the tear fluid.
Fig. 3. Concentration of timolol in the tear fluid (A), cornea (B), and aqueous humor (C) after instillation into human eyes. 
(0) timolol, (Lx) experimental data according to Phillips et al.", (A) experimental data according to Ellis et al.'), (- ) 
simulation line, (---) fitting line. Parameter values for simulation : KeTF (min-') = 0.18, VTF (Ml) = 0.19, KeAH (min-') = 0.013, 
Kt., (min-') = 0.020, Kt, (min-') = 0.086, VAH, (ml) = 0.142, D' (= DOR/L/L) (hr-1) = 0.32, K' (= KcRVCR) (cm3) = 0.006.
Fig. 4. Simulation curves of timolol in the tear fluid (A), 
cornea (B), and aqueous humor (C) after multiple instil-
lations into human eyes twice a day for 3 days. (-) simula-
tion line.
Drug Disposition in Tear Fluid 
 Fig. 2 shows the concentration-time profiles of timolol 
and fluorescein in the tear fluid after instillation into the 
eyes of human volunteers. These profiles almost showed a 
mono-exponential curve. Elimination rate constant and 
apparent distribution volume were estimated according to 
a one-compartment model and are listed in Table 1. These 
pharmacokinetic parameters of timolol were not signifi-
cantly different from those of fluorescein. The parameters 
calculated from an average concentration-time profile 
were used for the estimation of in vivo corneal penetration 
parameters and pharmacokinetic parameters for timolol 
in the aqueous humor. 
Estimation of in vivo penetration parameters and pharma-
cokinetic parameters 
 The concentrations of timolol in the aqueous humor 
after instillation into human eyes were obtained from the 
data reported previously',) and are shown in Fig. 3C. The 
estimation of in vivo penetration parameters of timolol 
were performed by using these data, the parameters in the 
tear fluid (Table 1), and the in vivo pharmacokinetic 
model (Fig. 1). Table 2 shows the estimated parameters 
for human with those for rabbits reported previously'). The 
parameters for human did not show a big difference from 
those for rabbits, The in vivo diffusion parameter and 
partition parameter for human were 0.32hr-' and 0.006 
cm3, respectively. The fitting curve was well consistent 
with the aqueous humor concentration of timolol after 
instillation as shown in Fig. 3C. The simulation curves of 
drug concentrations in the tear and cornea were also 
calculated from the pharmacokinetic model and parame-
ters (Table 1 and 2) and are shown in Figs. 3A and 3B.
Discussion 
 Compartment models frequently have applied to de-
scribe the pharmacokinetics of ophthalmic drugs in the 
eye",".").However, the application of this model to the 
corneal penetration of drugs may be limited in use. A main 
defect of the compartment model is lack of physical 
meaning of the model parameters in the drug penetration. 
An elimination of drug in the precorneal area is also 
progress under a non-steady state and the drug penetration 
across the cornea is a combined process of diffusion and 
partition. This behavior results in a phenomena called 
`back diffusion' of drug in the precorneal area and in the 
phenomenon of `flip-flop' of drug in the aqueous humor. 
Corneal penetration process of drugs may be better de-
scribed by the diffusion model based on Fick's second low. 
In fact, the in vitro penetration profiles of beta-blockers 
through an isolated cornea have been sufficiently analyzed 
by Fick's diffusion equation'-'). Therefore, we developed 
an in vivo kinetic model including a corneal diffusion 
process as shown in Fig. 1. In the previous report, this 
model and in vivo parameters well described the concentra-
tions of timolol in target sites such as tear, cornea, and 
aqueous humor after an instillation into rabbit eyes'). 
 The bioavailability and pharmacokinetics of instilled 
drugs in the anterior segment of the eye are mainly 
controlled by three factors: disposition of drugs in the 
precorneal area (tear), penetration of drugs in the cornea, 
and elimination and distribution of drugs in the aqueous 
chamber",,'). The physiological and anatomical similarity 
has been demonstrated between the eyes of human and 
rabbits'. The human eye is very close to rabbit eye in 
lacrimal volume, aqueous humor volume, corneal thick-
ness, and number of epithelial layers. However, there is a 
big difference in blinking rate, tear turnover, and presence 
of nictitating membrane. These indicate the importance of 
disposition in the precorneal area for carrying out animal 
scale up from rabbits to human. Therefore, the disposi-
tions of timolol and fluorescein in the tear fluid were 
examined after instillation into human eyes as shown in 
Fig. 2. The in vivo parameters in the tear fluid were 
estimated from these profiles and are shown in Table 1. 
 Fluorescein is a hydrophilic dye, that was often used as 
a probe to measure the physiological volume and turnover 
of the tear fluid and aqueous humor because of its 
impermeability on biological membranes. The elimination 
rate constant of fluorescein in the tear fluid was almost 
equal to a physiologic turnover rate",'). Timolol is a 
nonselective beta-blocker widely used in the treatment of 
open-angle glaucoma'). It is a lipophilic molecule. In the 
tear fluid, the elimination rate constant of timolol was 
not significantly different from that of fluorescein, 
indicating that the tear turnover mainly contributes to the 
drug disposition in the precorneal area.
 The estimation of other in vivo pharmacokinetic pa-
rameters for human were performed by using the aqueous 
humor concentrations of timolol reported by Phillips et 
al.') and Ellis et al.') after the data were standardized by 
dose. Their data were adequate for the estimation of 
parameters because many points in the aqueous humor 
were determined at various times after instillation. The 
estimated parameters for human are almost close to those 
for rabbits (Table 2). This similarity of human to rabbits 
could indicate the usefulness of rabbits as an animal model 
for human in ophthalmic chemotherapy. On the other 
hand, the clearance of timolol (KeAH X VAHC) in the aqueous 
humor of human was lower than that in rabbit. It might be 
explained by the species differences in elimination process, 
distribution to melanin tissue, and pharmacological 
response of beta-blocker31,32)
The mathematical model using in vivo pharmacokinetic 
parameters well described the concentrations of timolol in 
the tear and aqueous humor after instillation as shown in 
Figs. 3A and 3C. The model can calculate not only the drug 
concentrations in whole cornea (Fig. 3B) but also that in a 
portion of cornea principally. Fig. 4 shows the simulation 
profiles of timolol in the aqueous humor after multiple 
instillations into human eyes twice a day for 3 days based 
on the model and parameters. 
 A better understanding about the behavior of instilled 
drugs and a thorough knowledge of the physiology of the 
eye will result in improvement in chemotherapy. There-
fore, it is important to develop the in vivo pharma-
cokinetic model and in vivo parameters for predicting the 
drug concentration in the tear, cornea and aqueous humor. 
We established the in vivo mathematical model and 
parameters for timolol to describe the ocular absorption in 
human. This kinetic model will be effective to estimate the 
adequate regimen for ophthalmic chemotherapy and 
develop the ocular drug delivery systems.
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